Receptor Smoothened (SMO, SE = 4.8) activation by SHH ligands promotes tumor growth, while SHH/SMO pathway inhibition by the SMO antagonist, LDE225, in CAFs impairs tumor growth (Figure 2) [18]. This evidence concerns the gene SHH and neoplasm.